drugset

drugset / Trial / NCT00519662

Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors

NCT00519662 ↗

Phase 1 Completed 32 enrolled Sunesis Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in humans.

Timeline

Start: 2007-08
Primary completion: 2009-03
Completion: 2009-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SNS-314	Small molecule	30 mg/m2	—

Indications